在dezaparvovec基因治疗B型血友病的3期HOPE-B试验中,携带和不携带腺相关病毒血清5型中和抗体(滴度<1:700)的个体的出血保护持久性和因子IX活性

W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach
{"title":"在dezaparvovec基因治疗B型血友病的3期HOPE-B试验中,携带和不携带腺相关病毒血清5型中和抗体(滴度<1:700)的个体的出血保护持久性和因子IX活性","authors":"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach","doi":"10.1055/s-0042-1760524","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":217767,"journal":{"name":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B\",\"authors\":\"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach\",\"doi\":\"10.1055/s-0042-1760524\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":217767,\"journal\":{\"name\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"volume\":\"57 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1760524\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1760524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信